April 26, 2017
CTI Clinical Trial & Consulting Services to Sponsor and Present at 5th Annual Cell & Gene Investor Day
FOR IMMEDIATE RELEASE - Cincinnati, OH (April 26, 2017)
CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization, will present at the 5th Annual Cell & Gene Investor Day, taking place in Boston on April 27th. CTI’s Chief Executive Officer, Timothy J. Schroeder, will moderate Panel III, "Immuno-oncology: What are the Key Issues as First Products Approach Commercialization?"
“We’re honored to be sponsoring and part of the presentations at the 5th Annual Cell & Gene Investor Day, where so many thought leaders in the industry come together,” according to Schroeder. “We believe that CTI's extensive experience in cell and gene therapy, as well as our partnership with the Alliance demonstrate our belief that diagnosis and treatment paradigms will change dramatically in the near future based on these advances."
CTI is also a supporting member of the Alliance for Regenerative Medicine, and is a proud sponsor of the 5th Annual Cell & Gene Investor Day.
Schroeder, CEO and Founder of CTI, has over 35 years of clinical, academic, and industry experience in global drug and device development programs. The firm has supported more than 100 drug and device approvals, and currently works on behalf of approximately 120 global pharmaceutical and biotechnology companies. Prior to founding CTI, Tim held numerous faculty positions with the University of Cincinnati College of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995. Tim is currently a board member for over a dozen corporate and non-profit organizations, including Xavier University, which he attended. Tim was named as an EY Entrepreneur of the Year in 2015 and was recognized as Top Leader by the Enquirer Media in 2016.
About the Cell & Gene Investor Day
This one-day, high impact program provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe. For more information visit http://arminvestorday.com/
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com